Investors Overview Overview Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Corporate Factsheet Annual Reports Overview FRONT >> Quick Links Stock Info News Releases SEC Filings Analyst Coverage Presentations & Events Corporate Factsheet News Releases May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update May 04 2022 Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas FRONT >> News > View All View All News Events May 11 2022 at 4:30 PM EDT First Quarter 2022 Financial Results Mar 28 2022 at 4:30 PM EDT Fourth Quarter 2021 Financial Results Jan 10 2022 Biotech Showcase 2022 Virtual Conference FRONT > Events - View All View All Events Featured Videos CEO Spiro Rombotis addressing Cancer Resistance Toolkit Email AlertsRSS FeedsPrint Page
Overview FRONT >> Quick Links Stock Info News Releases SEC Filings Analyst Coverage Presentations & Events Corporate Factsheet News Releases May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update May 04 2022 Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas FRONT >> News > View All View All News Events May 11 2022 at 4:30 PM EDT First Quarter 2022 Financial Results Mar 28 2022 at 4:30 PM EDT Fourth Quarter 2021 Financial Results Jan 10 2022 Biotech Showcase 2022 Virtual Conference FRONT > Events - View All View All Events Featured Videos CEO Spiro Rombotis addressing Cancer Resistance
May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas
